The process of drug development from the laboratory bench to the market

Timothy J. Snape, Alison M. Astles

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

This article has aimed to highlight that medicines do not just happen and that, at best, it takes many years (approximately 10-12) to introduce a new drug to the market. Such is the high attrition rate of developing new drugs that it is inevitable that most projects are terminated before marketing and even at advanced stages of clinical studies. For example, for every 10,000 structures synthesised, 500 will reach animal testing, 10 will reach phase I clinical trials and only one will get to market, usually at a cost of approximately £444m. However, by continuing to draw on the knowledge and expertise of pharmaceutical scientists, as well as applying both new and established methods to drug development, we will undoubtedly continue to improve our chances of developing new drugs for the future.

Original languageEnglish
Pages (from-to)272-273
Number of pages2
JournalPharmaceutical Journal
Volume285
Issue number7618
Publication statusPublished - 9 Sep 2010
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Clinical Trials, Phase I
Marketing
Costs and Cost Analysis
Clinical Studies

Cite this

@article{f3fdd79d7b6747e3b998193227abb04a,
title = "The process of drug development from the laboratory bench to the market",
abstract = "This article has aimed to highlight that medicines do not just happen and that, at best, it takes many years (approximately 10-12) to introduce a new drug to the market. Such is the high attrition rate of developing new drugs that it is inevitable that most projects are terminated before marketing and even at advanced stages of clinical studies. For example, for every 10,000 structures synthesised, 500 will reach animal testing, 10 will reach phase I clinical trials and only one will get to market, usually at a cost of approximately £444m. However, by continuing to draw on the knowledge and expertise of pharmaceutical scientists, as well as applying both new and established methods to drug development, we will undoubtedly continue to improve our chances of developing new drugs for the future.",
author = "Snape, {Timothy J.} and Astles, {Alison M.}",
year = "2010",
month = "9",
day = "9",
language = "English",
volume = "285",
pages = "272--273",
journal = "Pharmaceutical Journal",
issn = "0031-6873",
publisher = "London: Pharmaceutical Society of Great Britain, 1933-",
number = "7618",

}

The process of drug development from the laboratory bench to the market. / Snape, Timothy J.; Astles, Alison M.

In: Pharmaceutical Journal, Vol. 285, No. 7618, 09.09.2010, p. 272-273.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - The process of drug development from the laboratory bench to the market

AU - Snape, Timothy J.

AU - Astles, Alison M.

PY - 2010/9/9

Y1 - 2010/9/9

N2 - This article has aimed to highlight that medicines do not just happen and that, at best, it takes many years (approximately 10-12) to introduce a new drug to the market. Such is the high attrition rate of developing new drugs that it is inevitable that most projects are terminated before marketing and even at advanced stages of clinical studies. For example, for every 10,000 structures synthesised, 500 will reach animal testing, 10 will reach phase I clinical trials and only one will get to market, usually at a cost of approximately £444m. However, by continuing to draw on the knowledge and expertise of pharmaceutical scientists, as well as applying both new and established methods to drug development, we will undoubtedly continue to improve our chances of developing new drugs for the future.

AB - This article has aimed to highlight that medicines do not just happen and that, at best, it takes many years (approximately 10-12) to introduce a new drug to the market. Such is the high attrition rate of developing new drugs that it is inevitable that most projects are terminated before marketing and even at advanced stages of clinical studies. For example, for every 10,000 structures synthesised, 500 will reach animal testing, 10 will reach phase I clinical trials and only one will get to market, usually at a cost of approximately £444m. However, by continuing to draw on the knowledge and expertise of pharmaceutical scientists, as well as applying both new and established methods to drug development, we will undoubtedly continue to improve our chances of developing new drugs for the future.

UR - http://www.scopus.com/inward/record.url?scp=77957707959&partnerID=8YFLogxK

M3 - Comment/debate

VL - 285

SP - 272

EP - 273

JO - Pharmaceutical Journal

JF - Pharmaceutical Journal

SN - 0031-6873

IS - 7618

ER -